Cardinal Health, Inc. (CAH) Q4 Fiscal Year 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $63.7 billion for Q4, up 6% year-over-year.

Operating Earnings: Grew 30% to $935 million.

EPS: Diluted EPS of $2.91, a 40% increase year-over-year; $0.31 of this growth attributed to a one-time IEEPA tariff refund.

Gross Profit: Increased 16% to $2.6 billion.

Adjusted Free Cash Flow: $5 billion for the year.

Tax Rate: Full-year tax rate of 19%, with Q4 at 22.5%.

2Strategic Updates and Business Highlights

Pharmaceutical and Specialty Solutions: Continued strong performance with robust demand and growth in specialty business, contributing significantly to overall results.

Global Medical Products and Distribution (GMPD): Progress made against improvement plans, though revenue declined 2% due to tariff-related payables.

Other Growth Businesses: Achieved $1.7 billion in revenue (7% growth) and $183 million in segment profit (14% growth).

Investments: $649 million in CapEx for the year, focusing on automation and technology to drive long-term growth.

Share Repurchase Program: Completed $1.35 billion in share repurchases during the year, with a new $4 billion revolver program announced.

3Forward Guidance and Outlook

Fiscal Year 2027 EPS Guidance: Expected growth of 13% to 15%, with EPS projected between $12.40 and $12.60.

Pharmaceutical Segment: Revenue growth projected at 3% to 5%, with profit growth of 8% to 11%.

GMPD Segment: Revenue growth of 2% to 4%, with profit expected to grow by approximately $50 million off the previous year's results.

Other Growth Businesses: Anticipated revenue growth of 11% to 13% and profit growth of 15% to 18%.

4Bad News, Challenges, or Points of Concern

GMPD Segment Decline: Revenue decreased by 2% due to tariff-related payables and lower distribution volumes.

Regulatory Environment: Potential headwinds from IRA price changes and 340B program impacts could affect customer volumes and profitability.

Input Cost Pressures: Rising costs in oil and petroleum products, which could impact distribution and logistics expenses.

Market Dynamics: The company is cautious about assuming outsized demand in the upcoming fiscal year, indicating a more normalized growth expectation.

5Notable Q&A Insights

Pharmaceutical Segment Performance: Executives noted strong momentum in Pharma, but clarified that they are not expecting the outsized demand experienced in FY26 to continue.

Regulatory Changes: Management is closely monitoring the impacts of regulatory changes, particularly concerning 340B and IRA, and emphasized their role in maintaining access and affordability in healthcare.

Investment Focus: Continued emphasis on investments in Specialty and at-Home Solutions, with a focus on scaling operations and improving service levels.

Customer Relationships: Renewed contracts with key customers, including CVS, were highlighted as a strategic advantage, although the impact of regulatory changes on these relationships remains a concern. Overall, Cardinal Health demonstrated strong financial performance in FY26, with a solid outlook for FY27, although challenges related to regulatory changes and market dynamics could pose risks.